STEZIPLA Trademark

Trademark Overview

On Wednesday, May 27, 2015, a trademark application was filed for STEZIPLA with the United States Patent and Trademark Office. The USPTO has given the STEZIPLA trademark a serial number of 86641987. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 8, 2019. This trademark is owned by Glaxo Group Limited. The STEZIPLA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric related diseases and disorders; Vaccines, excluding vaccines for the treatment or prevention of HIV/AIDS, infectious diseases, or viral or immune system related disorders and diseases
stezipla

General Information

Serial Number86641987
Word MarkSTEZIPLA
Filing DateWednesday, May 27, 2015
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 8, 2019
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 13, 2015

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric related diseases and disorders; Vaccines, excluding vaccines for the treatment or prevention of HIV/AIDS, infectious diseases, or viral or immune system related disorders and diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, June 2, 2015
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS
Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS

Trademark Events

Event DateEvent Description
Monday, July 8, 2019ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, July 8, 2019ABANDONMENT - NO USE STATEMENT FILED
Tuesday, December 11, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 10, 2018EXTENSION 5 GRANTED
Friday, November 30, 2018EXTENSION 5 FILED
Monday, December 10, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, November 30, 2018TEAS EXTENSION RECEIVED
Saturday, May 26, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 24, 2018EXTENSION 4 GRANTED
Thursday, May 24, 2018EXTENSION 4 FILED
Thursday, May 24, 2018TEAS EXTENSION RECEIVED
Friday, November 3, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 1, 2017EXTENSION 3 GRANTED
Wednesday, November 1, 2017EXTENSION 3 FILED
Wednesday, November 1, 2017TEAS EXTENSION RECEIVED
Friday, June 2, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 31, 2017EXTENSION 2 GRANTED
Wednesday, May 31, 2017EXTENSION 2 FILED
Wednesday, May 31, 2017TEAS EXTENSION RECEIVED
Saturday, December 3, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 1, 2016EXTENSION 1 GRANTED
Thursday, December 1, 2016EXTENSION 1 FILED
Thursday, December 1, 2016TEAS EXTENSION RECEIVED
Tuesday, June 7, 2016NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 26, 2016EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Wednesday, March 30, 2016CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Wednesday, March 30, 2016ASSIGNED TO PETITION STAFF
Wednesday, March 23, 2016TEAS POST PUBLICATION AMENDMENT RECEIVED
Friday, November 6, 2015EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, October 13, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 13, 2015PUBLISHED FOR OPPOSITION
Wednesday, September 23, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, September 2, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, September 1, 2015ASSIGNED TO EXAMINER
Tuesday, June 23, 2015TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, June 2, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, May 30, 2015NEW APPLICATION ENTERED IN TRAM

Related Keywords

stezipla disorders treatment pharmaceutical diseases preparations substances vaccines related dermatological hormonal